公开(公告)号：US20240287614A1

公开(公告)日：2024-08-29

申请号：US18441787

申请日：2024-02-14

申请人： UNIVERSITY OF MARYLAND, EASTERN SHORE

发明人： Bi-Dar Wang ,  Himali Gujrati ,  Siyoung Ha

IPC分类号： C12Q1/6886 ,  C12Q1/6851 ,  G01N33/574

CPC分类号： C12Q1/6886 ,  C12Q1/6851 ,  G01N33/57434 ,  C12Q2600/106 ,  C12Q2600/178

摘要： The present disclosure relates to the involvement of miR-34a-5p, miR-99b-5p, and miR-96-5p in certain cancers, as well as the use of agonists or antagonists thereof to treat the same.

公开(公告)号：US20240101706A1

公开(公告)日：2024-03-28

申请号：US18478239

申请日：2023-09-29

申请人： The Johns Hopkins University ,  Institute of Biotechnology CAS, V.V.I.

发明人： Cyril Barinka ,  Martin G. Pomper ,  Zora Novakova ,  Catherine A. Foss

IPC分类号： C07K16/30 ,  A61K47/68 ,  A61K49/00 ,  A61K51/10 ,  G01N33/574

CPC分类号： C07K16/3069 ,  A61K47/68 ,  A61K49/0032 ,  A61K49/0058 ,  A61K51/1072 ,  G01N33/57434 ,  A61K39/39558 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/92

摘要： The presently disclosed subject matter provides compositions and methods comprising isolated antibodies that can recognize human prostate-specific membrane antigen (PSMA). The presently disclosed antibodies can be used to for imaging and therapy of PSMA-expressing cancers, such as prostate cancer, in a subject.

公开(公告)号：US11820831B2

公开(公告)日：2023-11-21

申请号：US17489885

申请日：2021-09-30

申请人： APROGEN INC.

发明人： Yoo Ri Moon ,  Sangsoon Yoon ,  Jeong Won Hong ,  Eun Jung Kim ,  Da Bin Choi

IPC分类号： C07K16/40 ,  A61K47/68 ,  A61P35/00 ,  C12N5/16 ,  C12N15/85 ,  G01N33/532 ,  G01N33/574 ,  A61K39/395

CPC分类号： C07K16/40 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  C12N5/16 ,  C12N15/85 ,  G01N33/532 ,  G01N33/574 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57434 ,  G01N33/57438

摘要： Provided is an antibody that recognizes and binds to carbonic anhydrase or antigen-binding fragment, a nucleic acid molecule coding for the antibody or antigen-binding fragment, a vector carrying the nucleic acid molecule, a host cell including the nucleic acid molecule or the vector, and use of the antibody or antigen-binding fragment thereof in the alleviation, prevention, treatment or diagnosis of solid cancers.

公开(公告)号：US20230280346A1

公开(公告)日：2023-09-07

申请号：US18171569

申请日：2023-02-20

申请人： IMMUNIS.AI, INC.

发明人： Amin I. Kassis ,  Harry Stylli ,  Colleen Kelly ,  Geoffrey Erickson ,  Kirk J. Wojno

IPC分类号： G01N33/574 ,  C12Q1/6886

CPC分类号： G01N33/57434 ,  C12Q1/6886 ,  G01N2800/52 ,  C12Q2600/158 ,  G01N2500/00 ,  G01N2333/90 ,  G01N2333/7158 ,  G01N2333/46 ,  C12Q2600/106 ,  C12Q2600/118 ,  G01N2500/04 ,  G01N2800/50 ,  G01N2800/54

摘要： The invention described herein provides biological markers for the diagnosis, prognosis, and monitoring of prostate cancer

公开(公告)号：US11686731B2

公开(公告)日：2023-06-27

申请号：US15540295

申请日：2016-01-05

申请人： Ian Mills ,  Ingrid Jenny Guldvik

发明人： Ian Mills ,  Ingrid Jenny Guldvik

IPC分类号： G01N33/574

CPC分类号： G01N33/57434 ,  G01N2333/475 ,  G01N2333/4728 ,  G01N2333/96425 ,  G01N2800/52

摘要： The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to LRG1 protein markers for use in the diagnosis, prognosis, and determination of treatment of prostate cancer.

公开(公告)号：US20230176061A1

公开(公告)日：2023-06-08

申请号：US17884465

申请日：2022-08-09

申请人： HIGH DEVELOPMENT

发明人： Karla WILLIAMS ,  Hon Sing LEONG

IPC分类号： G01N33/574

CPC分类号： G01N33/57488 ,  G01N33/57415 ,  G01N33/57434

摘要： Described herein are methods for diagnosing high-risk cancer in a subject by detecting PolySialic Acid (polySia) in a biological sample obtained from the subject, or by detecting polySia and one or more tissue-specific markers in a biological sample obtained from the subject.

公开(公告)号：US11670585B1

公开(公告)日：2023-06-06

申请号：US17354942

申请日：2021-06-22

申请人： XILINX, INC.

发明人： Praful Jain

IPC分类号： H01L23/48 ,  H01L23/522 ,  H01L25/065 ,  H01L25/00 ,  H01L23/528 ,  C07K16/32 ,  C12Q1/6886 ,  G01N33/574

CPC分类号： H01L23/5228 ,  C07K16/32 ,  C12Q1/6886 ,  G01N33/57434 ,  H01L23/481 ,  H01L23/5222 ,  H01L23/5226 ,  H01L23/5286 ,  H01L25/0657 ,  H01L25/50 ,  C07K2317/565 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N2333/4703 ,  G01N2800/52 ,  H01L2224/0401 ,  H01L2224/0557 ,  H01L2225/06541 ,  H01L2225/06544 ,  H01L2225/06548

摘要： Active-on-active microelectronic devices are described. For example, a first die is on a second die with a bottom surface of a first substrate facing a top surface of a second substrate, respectively, to provide a die stack. The first and second dies each have metal layers in ILD layers to provide a first stack structure and a second stack structure, respectively. The first stack structure is interconnected to an upper end of a TSV of the first die. A metal layer of the second stack structure near a bottom surface of the first substrate is interconnected to a lower end of the TSV. A power distribution network layer of the second stack structure is located between lower and upper layers of the metal layers thereof. A transistor located at least in part in the second substrate is interconnected to the power distribution network layer to receive supply voltage or ground.

公开(公告)号：US11651863B2

公开(公告)日：2023-05-16

申请号：US16271827

申请日：2019-02-09

申请人： AstraZeneca Computational Pathology GmbH

发明人： Guenter Schmidt

IPC分类号： G16H50/30 ,  G16B25/10 ,  G16B45/00 ,  G16B20/00 ,  G16B40/00 ,  G16H40/63 ,  G01N33/574 ,  G16H30/40 ,  G16H50/20 ,  G16B40/20 ,  C12Q1/6886

CPC分类号： G16H50/30 ,  C12Q1/6886 ,  G01N33/57434 ,  G16B20/00 ,  G16B25/10 ,  G16B40/00 ,  G16B40/20 ,  G16B45/00 ,  G16H30/40 ,  G16H40/63 ,  G16H50/20 ,  G01N2570/00 ,  G01N2800/342 ,  G01N2800/52 ,  G01N2800/54 ,  G01N2800/7028

摘要： A method that provides a graphical indication of whether a patient will have cancer recurrence uses univariate and bivariate prognostic features that were generated as part of a minimal spanning tree (MST). The method determines the values of first and second features. A first value is measured by detecting objects in an image of tissue from the cancer patient stained with a protein-specific IHC biomarker. A second value is measured using objects marked with an mRNA-specific probe biomarker detected in the tissue. The first feature is the univariate prognostic feature for cancer recurrence in a cohort of cancer patients. A combination of the first and second features is the bivariate prognostic feature for cancer recurrence in the cohort. The first and second features are elements of the MST. Nodes of the MST represent the univariate features, edges represent the bivariate features, and edge weights represent prognostic significance of bivariate features.

公开(公告)号：US11644468B2

公开(公告)日：2023-05-09

申请号：US16498557

申请日：2018-03-30

申请人： Progastrine et Cancers S.à r.l.

发明人： Alexandre Prieur

IPC分类号： C07K16/26 ,  A61P35/00 ,  A61K39/395 ,  A61K39/00 ,  G01N33/574 ,  C07K16/30 ,  A61K45/06 ,  C07K16/22 ,  C07K16/28

CPC分类号： G01N33/57434 ,  A61K39/3955 ,  A61K39/39541 ,  A61K45/06 ,  A61P35/00 ,  C07K16/22 ,  C07K16/26 ,  C07K16/2863 ,  C07K16/3069 ,  G01N33/5748 ,  A61K2039/507 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  G01N2333/96411

摘要： The present invention relates to compositions and methods for the prevention or the treatment of prostate cancer, wherein said compositions comprise an antibody binding to progastrin and said methods comprise the use of an antibody binding to progastrin.

公开(公告)号：US20190252075A1

公开(公告)日：2019-08-15

申请号：US16237392

申请日：2018-12-31

申请人： Definiens AG

发明人： Guenter Schmidt

IPC分类号： G16H50/30 ,  C12Q1/6886 ,  G16H50/20 ,  G16B40/20

CPC分类号： G16H50/30 ,  C12Q1/6886 ,  G01N33/57434 ,  G01N2570/00 ,  G01N2800/342 ,  G01N2800/52 ,  G01N2800/54 ,  G01N2800/7028 ,  G16B20/00 ,  G16B25/10 ,  G16B40/00 ,  G16B40/20 ,  G16B45/00 ,  G16H30/40 ,  G16H40/63 ,  G16H50/20

摘要： An analysis and display system generates and displays a score indicative of whether cancer will recur in a patient. In a learning phase, a phenomic feature of tumor tissue is measured. A corresponding phenomic feature is defined. The phenomic feature may be measured through image analysis of digital images taken of tissue slices stained with IHC-based stains. A genomic feature of the tissue is also measured. This may entail obtaining a probe count indicative of a degree of expression of a particular gene. A bivariate feature is calculated using both the phenomic and genomic information. A network including the bivariate feature is displayed. In a diagnostic phase, raw phenomic and genomic data is obtained from a tissue sample taken from the patient. From the data, a score for the bivariate feature, and scores for the other features, are calculated. The score is a function of the underlying feature scores.